News

Nuvox Pharma announces that the FDA has allowed an Investigational New Drug (IND) application to initiate a Phase II clinical trial for its oxygen therapeutic, NVX-108, in patients with…
Read More...

Aimmune Therapeutics, Inc. announced the appointment of Eric Bjerkholt as Chief Financial Officer. Mr. Bjerkholt joins Aimmune from Sunesis Pharmaceuticals, Inc., where, over 13…
Read More...

Second Sight Medical Products, Inc. a developer, manufacturer and marketer of implantable visual prosthetics that are intended to provide some useful vision to blind patients announced…
Read More...

Lyndra, Inc. announced the closing of a $23 Million Series A financing, led by Polaris Partners, with participation from Quark Venture and GF Securities, Yonghua Capital, Healthlink…
Read More...

Icon Bioscience Inc. (IBI), a specialty biopharmaceutical company focused on utilizing its Verisome drug-delivery platform to develop unique intraocular eye-care therapeutics announced…
Read More...

BMS (Bristol-Myers Squibb) announced that it has entered into two separate agreements with Biogen and Roche to license to compounds. BMS-986168, an anti-eTau compound in development…
Read More...

Transgene (Paris:TNG), a company that designs and develops viral-based immunotherapies announces that the first patient with soft tissue sarcoma (STS) has been treated in the Phase 2…
Read More...

1CellBiO Inc announced today a research collaboration with UCB to validate and deploy the inDrop™ high throughput single cell RNA sequencing platform in order to better understand the…
Read More...

KYORIN Holdings, Inc. announced today that its wholly owned subsidiary, KYORIN Pharmaceutical Co., Ltd., has entered into a license agreement with Merck & Co., Inc., Kenilworth,…
Read More...

Neurocrine Biosciences’ Ingrezza (valbenazine) capsules has been approved by US FDA (food and Drug Administration) for treatment of tardive dyskinesia (TD). TD is characterised by…
Read More...

OncoMed Pharmaceuticals’ demcizumab (anti-DLL4, OMP-21M18) has failed to meet its primary endpoint in the Phase 2 YOSEMITE clinical trial in combination with Abraxane (paclitaxel…
Read More...

The U.S. Food and Drug Administration today approved supplemental applications for Sovaldi (sofosbuvir) and Harvoni (ledipasvir and sofosbuvir) to treat hepatitis C virus (HCV) in…
Read More...

PeptiDream Inc., a public Tokyo-based biopharmaceutical company announced today that it has entered into a multi-target discovery and optimization collaboration with US-based Janssen…
Read More...

Accenture announced its collaboration with BioCelerate to Advance Biopharmaceutical Innovations through Increased Insights in Research & Development. The R&D data sharing…
Read More...

Takeda Pharmaceutical Company Limited announced a strategic collaboration with NuBiyota LLC for the development of Microbial Ecosystem Therapeutic products for gastroenterology (GI)…
Read More...

Medivir has reported positive data from its phase II clinical trial of the topical, skin-directed histone deacetylase (HDAC) inhibitor, remetinostat, in early stage Cutaneous T-cell…
Read More...

IBM announced that its scientists have been granted a patent on machine learning models to predict therapeutic indications and side effects from various drug information sources. IBM…
Read More...

Jazz Pharmaceuticals plc announced that certain of its subsidiaries have entered into agreements with Hikma Pharmaceuticals PLC and related entities ("Hikma") resolving patent…
Read More...

Therapix Biosciences Ltd., a specialty clinical-stage pharmaceutical company specializing in the development of cannabinoid-based drugs, today announced that it has signed a sublicense…
Read More...

Ligand Pharmaceuticals announced that it has entered into commercial License and Supply Agreements (License Agreement) with Marinus Pharmaceuticals, Inc., granting rights to use…
Read More...